drugset / Trial / NCT00910663

Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

NCT00910663

Phase 1 Completed 60 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to compare the oral availability of a test product of Mycophenolate Mofetil 250 mg capsule to an equivalent oral dose of the commercially available reference product, CellCept® 250 mg capsule administered to healthy subjects under fed conditions.

Timeline

Start
2006-10
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 250 mg Oral

Indications

No indication recorded.